Fauzia Shaikh1, Marjorie G Zauderer2, Donata von Reibnitz1, Abraham J Wu1, Ellen D Yorke3, Amanda Foster1, Weiji Shi4, Zhigang Zhang4, Prasad S Adusumilli5, Kenneth E Rosenzweig6, Lee M Krug2, Valerie W Rusch5, Andreas Rimner7. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York. 7. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rimnera@mskcc.org.
Abstract
INTRODUCTION: Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D). METHODS: We analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan-Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure-free survival and progression-free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. RESULTS: The median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%). CONCLUSIONS: Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.
INTRODUCTION: Higher target conformity and better sparing of organs at risk with modern radiotherapy (RT) may result in higher tumor control and less toxicity. In this study, we compare our institutional multimodality therapy experience of adjuvant chemotherapy and hemithoracic intensity-modulated pleural RT (IMPRINT) with previously used adjuvant conventional RT (CONV) in patients with malignant pleural mesothelioma (MPM) treated with lung-sparing pleurectomy/decortication (P/D). METHODS: We analyzed 209 patients who underwent P/D and adjuvant RT (131 who received CONV and 78 who received IMPRINT) for MPM between 1974 and 2015. The primary end point was overall survival (OS). The Kaplan-Meier method and Cox proportional hazards model were used to calculate OS; competing risks analysis was performed for local failure-free survival and progression-free survival. Univariate analysis and multivariate analysis were performed with relevant clinical and treatment factors. RESULTS: The median age was 64 years, and 80% of the patients were male. Patients receiving IMPRINT had significantly higher rates of the epithelial histological type, advanced pathological stage, and chemotherapy treatment. OS was significantly higher after IMPRINT (median 20.2 versus 12.3 months, p = 0.001). Higher Karnofsky performance score, epithelioid histological type, macroscopically complete resection, and use of chemotherapy/IMPRINT were found to be significant factors for longer OS in multivariate analysis. No significant predictive factors were identified for local failure or progression. Grade 2 or higher esophagitis developed in fewer patients after IMPRINT than after CONV (23% versus 47%). CONCLUSIONS: Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo Journal: Lung Cancer Date: 2013-10-27 Impact factor: 5.705
Authors: Kenneth E Rosenzweig; Marjorie G Zauderer; Benjamin Laser; Lee M Krug; Ellen Yorke; Camelia S Sima; Andreas Rimner; Raja Flores; Valerie Rusch Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-18 Impact factor: 7.038
Authors: Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Edward F Miles; Nicole A Larrier; Christopher R Kelsey; Jessica L Hubbs; Jinli Ma; Sua Yoo; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-08 Impact factor: 7.038
Authors: Christian Thieke; Nils H Nicolay; Florian Sterzing; Hans Hoffmann; Falk Roeder; Seyer Safi; Juergen Debus; Peter E Huber Journal: Radiat Oncol Date: 2015-12-30 Impact factor: 3.481
Authors: Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder Journal: Strahlenther Onkol Date: 2019-03-26 Impact factor: 3.621